Minority Diabetes Initiative Act This bill authorizes grants for diabetes-related health care services in minority communities. The Department of Health and Human Services may make these grants to public and nonprofit health care providers.
Affordable Insulin for the COVID-19 Emergency Act This bill eliminates cost-sharing under the Medicare prescription drug benefit and Medicare Advantage for insulin and associated medical supplies during the public health emergency relating to COVID-19 (i.e., coronavirus disease 2019). The bill also allows beneficiaries to receive their insulin and supplies via mail order during the emergency period.
This resolution recognizes the disparity between wages paid to men and women, and its impact on women, families, and the nation and reaffirms Congress' commitment to supporting equal pay and to narrowing the gender wage gap.
This resolution expresses congressional disapproval of the rule submitted by the Equal Employment Opportunity Commission (EEOC) that revises the EEOC settlement process to provide employers with the factual and legal basis that the EEOC relied on to make a reasonable cause finding of a discriminatory practice.
This joint resolution eliminates the deadline for the ratification of the Equal Rights Amendment, which prohibits discrimination based on sex. The amendment was proposed to the states in House Joint Resolution 208 of the 92nd Congress, as agreed to in the Senate on March 22, 1972. The amendment shall be part of the Constitution whenever ratified by the legislatures of three-fourths of the states.
This resolution celebrates the successes of American Indian, Alaska Native, and Native Hawaiian women and the contributions they have made in the United States. The resolution also recognizes the importance of supporting equity, providing safety, and upholding the interests of these women.
This resolution designates March 2021 as National Women's History Month. The resolution also recognizes the celebration of such month as a time to reflect on the contributions that women have made to the United States.
This resolution calls on the United States to recommit itself to the promotion of disability rights and to the values enshrined in the Prologue Room at the Franklin Delano Roosevelt Memorial on the occasion of the 20th anniversary of the dedication of the Prologue Room. The resolution recognizes the important work of the disability community, and the historic campaign championed by that community, that led to the expansion of the memorial to include a statue that clearly and visibly depicts President Franklin Delano Roosevelt in a wheelchair. Finally, the resolution calls on the National Park Service and the National Park Foundation to continue to increase access to the memorial for individuals with disabilities and to support the development of accessible educational materials to ensure awareness is raised about the history of the memorial and disability rights.
Keeping Our Manufacturers from Being Unfairly taxed while Championing Health Act or KOMBUCHA This bill modifies the definition of brewer for purposes of the alcohol excise tax to exempt kombucha from such tax.
Save Oak Flat Act This bill repeals the requirement for the Department of Agriculture to convey the 2,422 acres of Forest Service land located in Tonto National Forest in Pinal County, Arizona, known as Oak Flat, to Resolution Copper Mining, LLC, in exchange for various parcels of land owned by Resolution Copper. Oak Flat is withdrawn from (1) entry, appropriation, or disposal under the public land laws; (2) location, entry, and patent under the mining laws; and (3) disposition under all laws pertaining to mineral and geothermal leasing or mineral materials.
Battleship Iowa National Museum of the Surface Navy Act of 2021 This bill designates the Battleship USS Iowa Museum located in Los Angeles, California, as the National Museum of the Surface Navy.
Prescription Drug Price Relief Act of 2021 This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug. Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population. The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.
